微小RNA30c表达与肝癌临床病理特征及预后的关系

Relationship between micro RNA-30c expression and clinicopathological features and prognosis of hepatocellular carcinoma

目的 研究hsa-miR-30c的相对表达量与肝癌患者病理因素的关系及对患者生存预后的影响。方法 收集2008-2010年中南大学湘雅医院普外科住院肝癌患者的手术切除样本共计30例。逆转录实时定量聚合酶链反应检测样本中hsa-miR-30c的相对表达量。Kaplan-Meier生存曲线进行预后分析。结果hsa-miR-30c表达量与性别、年龄、肿瘤大小、肿瘤分化程度及T分期无关（P〉0.05）,但在淋巴结受累组hsa-miR-30c表达明显下调,均值为（0.226±0.071）,而无淋巴结受累组为（0.891±0.154）,差异有统计学意义（P=0.010）。hsa-miR-30c低表达组增加了淋巴结转移的风险,调整后的风险比OR=5.09,95%CI：1.19-23.72（P=0.030）。生存分析表明,11例hsa-miR-30c低表达者中位生存时间（8.00±1.76）个月,低于19例hsa-miR-30c高表达组的（14.00±5.18）个月,差异有统计学意义（P=0.004）,提示hsa-miR-30c低表达组预后不良。结论 hsa-miR-30c的相对表达水平与肝癌的患病风险及预后相关。hsa-miR-30c的相对表达量作为肝癌诊断与预后的新型标志还需要进一步的系统研究。

[ Objective ] To investigate the relationship between the relative expression of hsa-miR-30c and the clinicopathological features and prognosis of hepatocellular carcinoma. [ Methods ] Thirty cases of hepatocellular carcinoma tissues were collected from the patients who had undergone resection between March 2008 and March 2010 in General Surgery Department, Xiangya Hospital of Central South University. The relative expression of hsa- miR-30c was validated by real-time reverse transcription-polymerase chain reaction （RT-PCR）. Prognosis was analyzed by the Kaplan-Meier survival curves. [ Results ] The expression of hsa-miR-30c was not associated with the gender, age, size, tumor differentiation and T stage （P 〉 0.05）. In lymphatic metastasis positive group, the expression of hsa-miR-30c was remarkably downregulated （0.226 ± 0.071） compared with that in lymphatic metastasis negative group （0.891 ± 0.154）. There were significant differences in lymphatic metastasis between positive and negative groups （P = 0.010）. Low expression of hsa-miR-30c increased risk of lymphatic metastasis, OR=5.09, 95%CI： 1.19N 23.72 （P = 0.030）. Kaplan-Meier survival curve indicated that patients with low expression of hsamir-30c had a significantly shorter survival time In = 11; median survival = （8.00 ± 1.76） months] compared to patients with high expression of hsa-miR-30c [n = 19; median survival = （14.00 ± 5.18） months, P = 0.004）. [Conclusions] The experi- ment showed that low expression of hsa-miR-30c was associated with hepatocellular carcinoma risk and prognosis. However, as a novel biomarker for the diagnosis and prognosis of hepatocellular carcinoma, the relative expression of hsa-miR-30c still needs to be systematically evaluated.